Patients with metastatic prostatic cancer were treated by means of an LHRH agonist, Buserelin, by nasal administration. The serum testosterone levels were permanently decreased to castration levels in all patients. The objective response rate (CR + PR) was 50%.
Administration, Intranasal Buserelin